

Reuse of the French National Health Insurance data for patients suffering from rare diseases: the Dromos project challenge

Intelligence artificielle et santé : approches interdisciplinaires

Nantes, 29 juin 2022

Anne-Sophie Jannot
annesophie.jannot@aphp.fr



 bndmr.fr



- ▶ Context
- ▶ The linkage challenges
- ▶ The methodological challenges

- ▶ Final objectives:
 - Describe the typical care pathways of rare disease patients
 - Quantify the cost associated with each disease
 - Describe inequalities in care and their links with territorial and socio-economic inequalities and the practices of expert centers

- ▶ Sources of data
 - National Health Data System
 - Rare Disease National Registry

The National Health Data System (SNDS)

DCIR

- Demographic area
- Date of death if applicable
- Ambulatory care reimbursements with dates of consultations
- Prescriptions
- Medical procedures
- Biological tests
- Medical devices
- Healthcare from other healthcare professionals


Référentiel

Records of chronic disease covered by the French reimbursement system

Uniform Hospital Discharge Data Set summarizing information about diagnoses, procedures and information about specific aspects of the hospital stay, e.g. a stay in an intensive care unit as well as the DRG assigned to the stay

Medical causes of death

SNIIR-AM :
Système National d'Information
Inter-Régime de l'Assurance-Maladie



- ▶ Offer the complete care pathways of all individuals in France over the last 10 years

How to identify patients suffering from a given rare disease in the SNDS?


- ▶ Diagnoses are coded using the « international classification of disease » (ICD-10) published by the world health organization
- ▶ Few diagnoses available in the SNDS:
 - Declared chronic diseases
 - Diagnoses during hospitalizations
- ▶ Specificity of rare diseases:
 - Not always declared
 - Not always hospitalized
 - No ICD-10 code available for most rare disease

Patients suffering from a given rare disease cannot be identified in the SNDS

What is the National Rare Disease Registry (BNDMR)?

- ▶ Collects a common dataset for each patient followed in a rare disease expert center at each visit
- ▶ Financed by the National Plan for Rare Disease

Avancement au 20/06/2022



What is the National Rare Disease Registry (BNDMR)?


▶ The RD French minimum data set (MDS)

The French MDS contains about 60 items, including :

- ▶ Patient identification
- ▶ Vital status
- ▶ Care pathway & activities
- ▶ Ante and neonatal data
- ▶ Treatment (orphan drugs)
- ▶ **Diagnosis (ORPHAcodes)**
- ▶ Diagnostic history and accuracy
- ▶ Phenotype (HPO / ICD-10)
- ▶ Genotype (HGNC / HGVS)



**Rare disease
diagnoses
classification**



Local information
systems

Clinical
datawarehouse

Linking BNDMR and SNDS to identify care pathways for rare diseases

Patient identifier= name,
surname, date of birth

▶ The RD French minimum data set (MDS)


The French MDS contains about 60 items, including :

- ▶ Patient identification
- ▶ Vital status
- ▶ Care pathway & activities
- ▶ Ante and neonatal data
- ▶ Treatment (orphan drugs)
- ▶ Diagnosis (ORPHAcodes)
- ▶ Diagnostic history and accuracy
- ▶ Phenotype (HPO / ICD-10)
- ▶ Genotype (HGNC / HGVS)




- ▶ No common identifier
- ▶ Two linkage strategies:
 - Direct: using patient identifier
 - Indirect: using

Patient identifier = NIR




Direct linkage

Si non reconnu:
suppression de
l'échantillon



Indirect linkage



Example of linkage with a registry

Many linkage variables are needed!

Didier, R., Gouysse, M., Eltchaninoff, H., Le Breton, H., Commeau, P., Cayla, G., ... & Gilard, M. (2020). Successful linkage of French large-scale national registry populations to national reimbursement data: improved data completeness and minimized loss to follow-up. *Archives of cardiovascular diseases*, 113(8-9), 534-541.

- ▶ Direct linkage:
 - Need for strong identity quality
 - Multiple actors involved (CNAV, ...)

- ▶ Indirect linkage:
 - Computationally intensive (+65 millions of people in SNDS)
 - Need for many common variables to obtain a high linkage rate


Modeling care pathways: Methodological challenges

- ▶ Final objectives:
 - Describe the typical care pathways of rare disease patients
 - Quantify the cost associated with each disease
 - Describe inequalities in care and their links with territorial and socio-economic inequalities and the practices of expert centers

- ▶ Challenges using SNDS:
 - Thousands of variables
 - Each patient is followed at a different period of his/her life/disease: how to compare a child just diagnosed with an adult having been diagnosed at adult age 20 years ago?
 - Treatments evolve over time

How to describe the typical care pathways of rare disease patients?


- ▶ Visual approach focusing on relevant variables defined by expert




- ▶ Advantage: easy to interpret
- ▶ Limitation: need to define relevant variables, no subgroup definition, limited number of considered variables

How to describe the typical care pathways of rare disease patients?

► Process mining strategies



Can only be applied to events -> what to do with drugs?



No clear subgroups
Difficult to interpret

Giannoula, A., Gutierrez-Sacristan, A., Bravo, A., Sanz, F., Furlong, I. L. (2017). Identifying temporal patterns in patient disease trajectories using dynamic time warping : a population-based study. *Nature Scientific reports*


How to describe the typical care pathways of rare disease patients?

- ▶ Other approaches to handle longitudinal data: methods to cluster longitudinal data
 - Raw-based clustering
 - Feature based clustering (exemple: tsfresh)
 - Model-based clustering (mixture models)

- ▶ Limits:
 - Number of subgroups to specify a priori
 - High dimensional longitudinal modelling is challenging
 - Missing data are not handled


How to describe the typical care pathways of rare disease patients?

- ▶ Specific issue for SNDS data : different lengths of follow-up for each patient → truncated data



How to describe the typical care pathways of rare disease patients?

- ▶ Cluster tracking strategy:
 - Align patients (same age, start of the disease)
 - Cluster at each time step
 - Track clusters



Tracking temporal clusters from patient networks, Judith Lambert, Anne Louise Leutenegger, Anne Sophie Jannot, Anaïs Baudot, ongoing work

How to describe the typical care pathways of rare disease patients?


Age : 60

Patient	Aspirin	Combinations	Clopidogrel	Dabigatran	Enoxaparin	Fluindione	Fondaparinux	Tinzaparin
A	12	0	0	0	0	0	0	0
B	12	0	0	0	0	0	0	0
C	0	0	0	0	8	0	0	0
D	10	0	0	0	0	0	0	0
E	11	0	0	0	0	0	0	0
F	1	1	1	1	0	0	0	0
G	0	0	0	0	0	10	0	3
H	0	0	0	0	0	0	2	2


Combinations : Combinations of platelet aggregation inhibitors

	Cosine similarity	Jaccard index	Euclidean distance
A/B	1	1	1
C/D	0	0	0.54
E/F	0.5	0.25	0.64
G/H	0.20	0.33	0.63

How to describe the typical care pathways of rare disease patients?




How to describe the typical care pathways of rare disease patients?



Need to define subgroups resulting in small sample sizes

Poizeau, F., Kerbrat, S., Happe, A., Rault, C., Drezen, E., Balusson, F., ... & Dupuy, A. (2021). Patients with metastatic melanoma receiving anticancer drugs: Changes in overall survival, 2010–2017. *Journal of Investigative Dermatology*, 141(4), 830-839.

How to describe the typical care pathways of rare disease patients?



Poizeau, F., Kerbrat, S., Happe, A., Rault, C., Drezen, E., Balusson, F., ... & Dupuy, A. (2021). Patients with metastatic melanoma receiving anticancer drugs: Changes in overall survival, 2010–2017. *Journal of Investigative Dermatology*, 141(4), 830-839.

- ▶ July 2020: agreement of the scientific committee of French Data Protection Agency (CESRESS)
- ▶ May 2021: agreement from the French Data Protection Agency (CNIL)
- ▶ Access denied for direct linkage: new agreement needed for indirect linkage
- ▶ New agreement still in process.....

Reuse of the French National Health Insurance data for patients suffering from rare diseases: the Dromos project challenge

Intelligence artificielle et santé : approches interdisciplinaires

Nantes, 29 juin 2022

Anne-Sophie Jannot
annesophie.jannot@aphp.fr



bndmr.fr

